Grant: Alliance Grants
University of Alberta
$30,000.00
Modeling and optimal control of integrated continuous monoclonal antibody manufacturing processes _x000d_
FY 2020-21
Summary
Drugs based on mAbs play an indispensable role in biopharmaceutical industry in aspects of therapeutic and market potentials. In therapy and diagnosis applications, mAbs are widely used for the treatment of autoimmune diseases, and cancer, etc. According to a recent publication, mAbs also show promising results in the treatment of COVID-19. Until September 22, 2020, 94 therapeutic mAbs have been approved by U.S. Food & Drug Administration (FDA) and the number of mAbs approved within 2010-2020 is three times more than those approved before 2010. In terms of its market value, it is expected to reach a value of $198.2 billion in 2023. Thus, increasing the production capacity of mAb manufacturing processes is immediately necessary due to the explosive growth in mAb market. Canada is an active and competitive contributor to the development of high capacity mAb manufacturing processes. Integrated continuous manufacturing of mAbs represents the state-of-the-art in mAb manufacturing and has attracted a lot of attention. However, there is no existing mathematical model of the integrated manufacturing process and there is no optimal control algorithm of the entire integrated process. This project will fill the knowledge gaps by first developing a mathematical model of the integrated continuous manufacturing process of mAbs. The developed model will be validated using available data in the literature as well as potential data available from our industrial partner's clients. Based on the model, the machine-learning-based optimal control algorithm will be trained, assessed, and refined to get it ready for its implementation to industrial mAb manufacturing processes. This project will (a) further enhance the competitiveness of Canada in biopharmaceutical industry, (b) train highly qualified personnel (HQP) that have interdisciplinary backgrounds in biopharmaceutical and control engineering, and (c) may create more job opportunities in the partner organization in the near future.
Program
Alliance Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
558299-2020
Name nom
Liu, Jinfeng
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Modeling and optimal control of integrated continuous monoclonal antibody manufacturing processes _x000d_
Keyword
NSERC
Application summary
Drugs based on mAbs play an indispensable role in biopharmaceutical industry in aspects of therapeutic and market potentials. In therapy and diagnosis applications, mAbs are widely used for the treatment of autoimmune diseases, and cancer, etc. According to a recent publication, mAbs also show promising results in the treatment of COVID-19. Until September 22, 2020, 94 therapeutic mAbs have been approved by U.S. Food & Drug Administration (FDA) and the number of mAbs approved within 2010-2020 is three times more than those approved before 2010. In terms of its market value, it is expected to reach a value of $198.2 billion in 2023. Thus, increasing the production capacity of mAb manufacturing processes is immediately necessary due to the explosive growth in mAb market. Canada is an active and competitive contributor to the development of high capacity mAb manufacturing processes. Integrated continuous manufacturing of mAbs represents the state-of-the-art in mAb manufacturing and has attracted a lot of attention. However, there is no existing mathematical model of the integrated manufacturing process and there is no optimal control algorithm of the entire integrated process. This project will fill the knowledge gaps by first developing a mathematical model of the integrated continuous manufacturing process of mAbs. The developed model will be validated using available data in the literature as well as potential data available from our industrial partner's clients. Based on the model, the machine-learning-based optimal control algorithm will be trained, assessed, and refined to get it ready for its implementation to industrial mAb manufacturing processes. This project will (a) further enhance the competitiveness of Canada in biopharmaceutical industry, (b) train highly qualified personnel (HQP) that have interdisciplinary backgrounds in biopharmaceutical and control engineering, and (c) may create more job opportunities in the partner organization in the near future.